MX2017007748A - Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). - Google Patents

Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk).

Info

Publication number
MX2017007748A
MX2017007748A MX2017007748A MX2017007748A MX2017007748A MX 2017007748 A MX2017007748 A MX 2017007748A MX 2017007748 A MX2017007748 A MX 2017007748A MX 2017007748 A MX2017007748 A MX 2017007748A MX 2017007748 A MX2017007748 A MX 2017007748A
Authority
MX
Mexico
Prior art keywords
fused ring
nr4r5
ring heteroaryl
heteroaryl compounds
trk inhibitors
Prior art date
Application number
MX2017007748A
Other languages
English (en)
Other versions
MX383885B (es
Inventor
Choi Soongyu
Kim Moonsoo
Lee Chaewoon
Lee Gilnam
YOON Cheolhwan
Seo Jeongbeob
Lee Minwoo
JEONG Hankyul
Choi Hyang
Nam Lee Ki
Kyoung Kim Hye
Kim Misoon
Eun Jung Myung
Jung Kim Hyun
Hak Kim Jay
LEE II Jae
Original Assignee
Cmg Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cmg Pharmaceutical Co Ltd filed Critical Cmg Pharmaceutical Co Ltd
Publication of MX2017007748A publication Critical patent/MX2017007748A/es
Publication of MX383885B publication Critical patent/MX383885B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La descripción proporciona compuestos químicos novedosos representados por la Fórmula I o una sal, solvato, polimorfo, éster, tautómero o profármaco farmacéuticamente aceptable de los mismos. Los compuestos pueden utilizarse como un inhibidor del Trk y son útiles en el tratamiento del dolor, cáncer, inflamación, enfermedad neurodegenerativa y ciertas enfermedades infecciosas. (ver Fórmula). En algunos compuestos de la Fórmula I, Q es -CH=CR3C (O) NR4R5, -C?CC (O) NR4R5, o (ver Fórmula).
MX2017007748A 2014-12-15 2015-12-14 Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirosina cinasa (trk). MX383885B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462092193P 2014-12-15 2014-12-15
PCT/IB2015/002521 WO2016097869A1 (en) 2014-12-15 2015-12-14 Fused ring heteroaryl compounds and their use as trk inhibitors

Publications (2)

Publication Number Publication Date
MX2017007748A true MX2017007748A (es) 2018-01-30
MX383885B MX383885B (es) 2025-03-14

Family

ID=56110505

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017007748A MX383885B (es) 2014-12-15 2015-12-14 Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirosina cinasa (trk).

Country Status (17)

Country Link
US (1) US9701681B2 (es)
EP (2) EP3233863B1 (es)
JP (1) JP6609631B2 (es)
KR (2) KR102659741B1 (es)
CN (1) CN107207514B (es)
AU (1) AU2015365587B2 (es)
BR (1) BR112017012755B1 (es)
CA (1) CA2971024C (es)
DK (1) DK3233863T3 (es)
ES (1) ES2983908T3 (es)
FI (1) FI3233863T3 (es)
HR (1) HRP20240937T1 (es)
HU (1) HUE067779T2 (es)
MX (1) MX383885B (es)
PL (1) PL3233863T3 (es)
RU (1) RU2708674C2 (es)
WO (1) WO2016097869A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2350075T3 (da) 2008-09-22 2014-05-26 Array Biopharma Inc Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
HRP20191283T1 (hr) 2014-01-24 2019-10-18 Turning Point Therapeutics, Inc. Diaril makrocikli kao modulatori protein kinaze
EP3218380B1 (en) 2014-11-16 2021-03-17 Array Biopharma, Inc. Preparation of a crystalline form of (s)-n-(5-((r)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP4397665A3 (en) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
BR112018003588A2 (pt) 2015-08-26 2018-09-25 Blueprint Medicines Corp compostos e composições úteis para tratamento de distúrbios relacionados ao ntrk
TN2019000271A1 (en) 2015-10-26 2021-01-07 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
RU2018122089A (ru) 2015-11-19 2019-12-25 Блюпринт Медсинс Корпорейшн Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
IL304018A (en) 2016-04-04 2023-08-01 Loxo Oncology Inc Liquid formulations of (S)-N-(5-((R)-2-(5,2-difluorophenyl)-pyrrolidine-1-yl)-pyrazolo[5,1-A]pyrimidin-3-yl)-3 -hydroxypyrrolidine-1-carboxamide
ES2952056T3 (es) 2016-05-18 2023-10-26 Loxo Oncology Inc Preparación de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
JOP20190092A1 (ar) * 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JP7046940B2 (ja) * 2016-10-28 2022-04-04 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 神経栄養因子チロシンキナーゼ受容体阻害剤として用いられるアミノピラゾロピリミジン化合物
WO2018152134A1 (en) * 2017-02-14 2018-08-23 Research Triangle Institute Proline-based neuropeptide ff receptor modulators
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
US10738033B2 (en) 2017-05-31 2020-08-11 Nantbio, Inc. Trk inhibition
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
PL3724191T3 (pl) * 2017-12-15 2022-04-25 Pyramid Biosciences, Inc. Pochodne 5-(2-(2,5-difluorofenylo)pirolidyn-1-ylo)-3-(1h-pirazol-1-ilo)pirazolo[1,5-a]pirymidyny i pokrewne związki jako inhibitory kinaz trk do leczenia nowotworu
CN108218754B (zh) * 2018-01-23 2021-05-07 广东赛烽医药科技有限公司 一种2-(2,5-二氟苯基)吡咯烷的制备方法
US11464780B2 (en) 2018-02-28 2022-10-11 Simcere Pharmaceutical Co. Ltd. Pyrazolopyrimidine derivative and use thereof
JP7294677B2 (ja) 2018-03-14 2023-06-20 フォチョン・ファーマシューティカルズ・リミテッド ＴＲＫキナーゼ阻害剤としての置換（２－アザビシクロ［３．１．０］ヘキサン－２－イル）ピラゾロ［１，５－ａ］ピリミジン化合物及び置換（２－アザビシクロ［３．１．０］ヘキサン－２－イル）イミダゾ［１，２－ｂ］ピリダジン化合物
US20210023086A1 (en) 2018-03-29 2021-01-28 Loxo Oncology, Inc. Treatment of trk-associated cancers
CN108484361B (zh) * 2018-05-11 2022-09-30 弈柯莱生物科技(上海)股份有限公司 (s)-4-氯-1-(2,5)-二氟苯基丁-1-醇及其制备方法和应用
CN110294761B (zh) * 2018-06-08 2020-09-08 南京雷正医药科技有限公司 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物
CN110577532B (zh) * 2018-06-08 2022-06-03 江苏威凯尔医药科技有限公司 原肌球蛋白受体激酶抑制剂及其制备方法和应用
WO2019233461A1 (zh) * 2018-06-08 2019-12-12 江苏威凯尔医药科技有限公司 原肌球蛋白受体激酶抑制剂及其制备方法和应用
GB201811825D0 (en) 2018-07-19 2018-09-05 Benevolentai Bio Ltd Organic compounds
CN108794370A (zh) * 2018-07-31 2018-11-13 上海弈柯莱生物医药科技有限公司 一种拉罗替尼中间体的制备方法
CN110857304B (zh) * 2018-08-24 2021-05-18 北京富龙康泰生物技术有限公司 Trk抑制剂、其制备方法和用途
CN109053525B (zh) * 2018-09-25 2020-05-05 成都福柯斯医药技术有限公司 一种(r)-2-(2-取代-5-氟苯)吡咯烷的制备方法
US11414431B2 (en) * 2018-10-15 2022-08-16 Nimbus Lakshmi, Inc. Substituted pyrazolo[1,5-a]pyrimidines as TYK2 inhibitors
CN111138333B (zh) * 2018-11-02 2023-05-23 上海复星星泰医药科技有限公司 一种(r)-2-(2,5-二氟苯基)-吡咯烷的制备方法
PH12021551304A1 (en) * 2018-12-07 2022-05-16 Betta Pharmaceuticals Co Ltd Tyrosine kinase inhibitors, compositions and methods there of
CN111302995A (zh) * 2018-12-12 2020-06-19 上海复星星泰医药科技有限公司 一种2-(2,5-二氟苯基)-吡咯烷消旋体的制备方法
CN109593803A (zh) * 2018-12-24 2019-04-09 上海健康医学院 (r)-2-(2,5-二氟苯基)吡咯烷或其盐的制备方法
CN111362946A (zh) * 2018-12-25 2020-07-03 上海度德医药科技有限公司 一种药物化合物及其组合物和应用
WO2020187291A1 (zh) * 2019-03-19 2020-09-24 华中师范大学 吡唑并嘧啶化合物和药物组合物及其应用
WO2020224626A1 (zh) * 2019-05-08 2020-11-12 浙江同源康医药股份有限公司 用作激酶抑制剂的化合物及其应用
CN114258394B (zh) * 2019-08-28 2024-04-23 南京再明医药有限公司 一种致癌性融合激酶抑制剂的晶型及其应用
CN114641478B (zh) * 2019-10-30 2024-07-02 南京再明医药有限公司 吡唑并嘧啶类化合物的制备方法及其中间体
CN112979654B (zh) * 2019-12-16 2024-03-19 赛诺哈勃药业（成都）有限公司 杂芳基稠环化合物、其制备方法及应用
WO2021148807A1 (en) 2020-01-22 2021-07-29 Benevolentai Bio Limited Pharmaceutical compositions and their uses
CN111302997B (zh) * 2020-04-15 2022-03-29 江苏恒沛药物科技有限公司 “一锅法”制备拉罗替尼中间体的方法
WO2021211882A1 (en) * 2020-04-15 2021-10-21 Pyramid Biosciences, Inc. Methods for preparing tyrosine receptor kinase inhibitors
CN111393347B (zh) * 2020-04-30 2020-11-17 安徽德信佳生物医药有限公司 一种拉洛替尼中间体的合成方法
CN115551863A (zh) * 2020-06-11 2022-12-30 贝达药业股份有限公司 酪氨酸激酶抑制剂的盐型、晶型、药物组合物及其用途
CN114437075B (zh) * 2020-11-03 2026-01-30 上海瑶琪生物科技有限公司 用作ntrk激酶抑制剂的化合物及其应用
KR102541026B1 (ko) 2020-11-11 2023-06-12 주식회사 한독 Trk 억제제 화합물의 제조 방법
CN116102464B (zh) * 2021-11-10 2024-11-05 凯特立斯（深圳）科技有限公司 一种不对称氢化制备氨基醇的方法及其应用
WO2025107298A1 (zh) * 2023-11-24 2025-05-30 浙江同源康医药股份有限公司 晶体、药物组合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019507B1 (ru) 2008-05-13 2014-04-30 Айрм Ллк Конденсированные азотсодержащие гетероциклы и содержащие их композиции в качестве ингибиторов киназы
PT3106463T (pt) 2008-10-22 2018-05-18 Array Biopharma Inc Compostos de pirazolo[1,5-]pirimidina substituídos como inibidores de cinase trk
RU2539568C2 (ru) 2008-10-31 2015-01-20 Дженентек, Инк. Пиразолопиримидиновые соединения-ингибиторы jak и способы
AR077468A1 (es) * 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
WO2011029027A1 (en) 2009-09-03 2011-03-10 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
RU2735545C2 (ru) * 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
WO2012034095A1 (en) * 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
CN104302649B (zh) * 2012-03-09 2017-06-23 莱西肯医药有限公司 基于吡唑并[1,5‑a]嘧啶的化合物、包含它们的组合物及其使用方法

Also Published As

Publication number Publication date
JP2017538766A (ja) 2017-12-28
AU2015365587B2 (en) 2020-07-23
BR112017012755B1 (pt) 2023-11-14
BR112017012755A2 (pt) 2017-12-26
ES2983908T3 (es) 2024-10-28
CA2971024A1 (en) 2016-06-23
RU2017125025A (ru) 2019-01-17
WO2016097869A4 (en) 2016-08-04
US20160168156A1 (en) 2016-06-16
CN107207514B (zh) 2020-01-24
EP4420732A2 (en) 2024-08-28
EP4420732A3 (en) 2024-11-27
CA2971024C (en) 2023-09-26
KR20170095919A (ko) 2017-08-23
EP3233863B1 (en) 2024-04-10
WO2016097869A1 (en) 2016-06-23
DK3233863T3 (da) 2024-07-15
CN107207514A (zh) 2017-09-26
AU2015365587A1 (en) 2017-08-03
RU2708674C2 (ru) 2019-12-11
HUE067779T2 (hu) 2024-11-28
PL3233863T3 (pl) 2024-11-12
FI3233863T3 (fi) 2024-07-10
KR20240055170A (ko) 2024-04-26
RU2017125025A3 (es) 2019-06-21
EP3233863A4 (en) 2018-06-06
EP3233863A1 (en) 2017-10-25
HRP20240937T1 (hr) 2024-10-25
US9701681B2 (en) 2017-07-11
KR102659741B1 (ko) 2024-04-23
MX383885B (es) 2025-03-14
JP6609631B2 (ja) 2019-11-20

Similar Documents

Publication Publication Date Title
MX2017007748A (es) Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk).
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
WO2017205536A3 (en) Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
SG10201811384TA (en) Mnk inhibitors and methods related thereto
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
MX2015012431A (es) Pirrol amida como inhibidores.
MX2020001717A (es) Inhibidores macrociclicos de mcl-1 y metodos de uso.
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
TN2017000485A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MY194116A (en) Pharmaceutical compounds
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2016002718A (es) Derivados de ceto-imidazopiridina como moduladores del receptor huerfano relacionado con receptor retinoide (porc).
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2019004375A (es) Inhibidores de bromodominios.
EA201792265A1 (ru) Способы лечения сердечно-сосудистых заболеваний
MX2019004187A (es) Inhibidores de bromodominios.
PH12016502480A1 (en) Compounds, pharmaceutical composition and their use in treating neurodegenerative diseases
MX2018002177A (es) Nuevo derivado de catecol y composicion farmaceutica que comprende el mismo.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
EA201990686A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы